GHK-Cu: The Copper Peptide, Separating Evidence From Hype

Few skincare ingredients have a backstory as long, or a fan base as loud, as GHK-Cu. Online it gets called a “master regulator” that can “reset” your genes, rebuild collagen, regrow hair, and heal almost anything. Some of those claims come from real science. Others stretch a modest body of evidence far past what it can support. This article covers what GHK-Cu is, where it came from, what the studies show and don’t show, and where it stands with regulators as of November 2026.

What GHK-Cu is

GHK is a tripeptide, a chain of just three amino acids: glycine, histidine, and lysine (glycyl-L-histidyl-L-lysine). It occurs naturally in human plasma, saliva, and urine. It binds copper(II) ions tightly, and the copper-bound form is called GHK-Cu. Reviews by the peptide’s discoverer report that GHK levels in the body decline with age [2]. That observation helped make GHK-Cu attractive as an “anti-aging” ingredient.

On cosmetic labels, GHK-Cu usually appears as copper tripeptide-1, its ingredient name in cosmetics [3]. It is found in serums, creams, and eye products, usually at very low concentrations.

How it was discovered

In 1973, Loren Pickart and Melvin Thaler described a small peptide in human serum that prolonged the survival of normal liver cells in culture and also stimulated growth in liver cancer (hepatoma) tissue [1]. Later reviews by Pickart’s group describe the original observation like this: something in human albumin made older liver tissue produce proteins more like younger tissue did, and the active factor was eventually identified as GHK [2].

The detail about cancer cells deserves attention. The very first paper on GHK reported growth stimulation in neoplastic liver cells [1]. That doesn’t mean GHK-Cu causes cancer, and later computational work pointed in the opposite direction (see below). It does show why the long-term biology of a growth-promoting signal is worth studying carefully rather than assuming it’s harmless.

A note on sources: much of the review literature on GHK-Cu, including several of the most-cited reviews, was written by Pickart and his longtime collaborator Anna Margolina [2, 5]. Their work is published in peer-reviewed journals. Still, readers should know that a large share of the summaries come from the discoverer’s own group. A 2026 systematic review estimated that about 35% of the primary GHK-Cu literature includes Pickart or Margolina as authors. The reviewers flagged this as a limit on how independent the evidence is [6].

Proposed mechanisms

Most of what we know about how GHK-Cu might work comes from cell cultures and animal models:

• Collagen and matrix production. In a 1988 study, GHK-Cu increased collagen synthesis by cultured fibroblasts (the cells that build skin’s support structure) at extremely low concentrations, without increasing cell numbers [4].
• Tissue remodeling. Reviews describe effects on glycosaminoglycans, decorin, and the balance between enzymes that break down tissue (metalloproteinases) and their inhibitors. They also describe effects on the immune and blood-vessel cells that move into wounds [2].
• Anti-inflammatory and antioxidant activity. These are reported in lab models and summarized in reviews [2, 5].
• Copper delivery. Copper is a required cofactor for enzymes involved in connective tissue formation. GHK’s strong binding of copper is often proposed as part of how it works [2, 5].

These mechanisms make biological sense, and they are fairly consistent across lab studies. But a mechanism seen in a dish does not show that a cream or injection produces a meaningful benefit in people.

What the research shows

Skin aging and cosmetics

This is the most common use of GHK-Cu, and it is where people most often assume the evidence is strong.

Pickart’s reviews describe cosmetic studies in which GHK-Cu products improved skin firmness, elasticity, fine lines, photodamage, and uneven pigmentation [2]. Many of those studies were small and short. Some were reported in cosmetic-industry settings rather than full peer-reviewed clinical trial reports, which makes them hard to evaluate independently.

The independent picture is more modest. A 2026 systematic review screened more than 1,200 records and included 64 studies. Only 11 involved humans. Eight of those 11 used GHK-Cu only as a comparator, not as the treatment being tested. That left just three human studies that directly evaluated GHK-Cu: a pilot trial, a split-face study, and a case series. The authors called the human literature “thin and fragmented” and concluded that adequately powered trials are still needed [6].

One of the few randomized studies in a peer-reviewed medical journal gives a useful reality check. Thirteen patients completed a trial of skincare with or without a copper tripeptide complex after CO2 laser resurfacing around the mouth. Blinded evaluators found no significant difference in how quickly redness resolved or in wrinkle and skin-quality scores. Patients in the GHK-Cu group did report greater satisfaction with their skin quality [7]. That pattern is common in cosmetic research: people often feel a difference that objective measurements don’t confirm.

Wound healing

Animal data here are fairly encouraging. In rats with wounds on skin flaps that had poor blood supply, topical tripeptide-copper complex shrank wounds faster than a vehicle or no treatment. It also lowered markers of inflammation and tissue breakdown [8].

Human trials are few, old, and mixed:

• Diabetic foot ulcers (positive). A multicenter, randomized, evaluator-blinded, vehicle-controlled study of a GHK-Cu gel in people with diabetic neuropathic ulcers was published in 1994. The abstract reports better closure of plantar (sole-of-foot) ulcers with the gel than with the vehicle (median closure about 98.5% vs. 60.8%) and fewer infections [9]. The headline results are reported for plantar ulcers and a subgroup of larger ulcers. Readers can’t fully judge the overall trial from the abstract alone.
• Venous leg ulcers (negative). A 1992 randomized, evaluator-blinded trial in 86 evaluable patients compared silver sulfadiazine cream, a 0.4% tripeptide-copper complex cream, and a placebo. Silver sulfadiazine reduced ulcer size. The copper peptide did no better than placebo [10].

GHK-Cu has not become an approved wound-care drug in the U.S. The large confirmatory trials needed to settle the question have not been published.

Hair

Claims about GHK-Cu for hair growth are popular, but the direct evidence is thin. A 1993 review of hair-growth agents reported that a copper-binding peptide (PC1031) enlarged hair follicles in “fuzzy” rats, with an effect resembling topical minoxidil [11]. A 2007 laboratory study found that a related copper tripeptide, AHK-Cu (not GHK-Cu), lengthened human hair follicles grown outside the body and increased the growth of dermal papilla cells [12].

Both findings are preclinical, and one doesn’t involve GHK-Cu itself. We found no well-controlled published human trial showing that GHK-Cu treats hair loss.

Gene-expression (“Connectivity Map”) studies

This is where the boldest claims come from. The Connectivity Map is a research database that records how cultured cells change their gene activity after exposure to various compounds. Scientists can enter a disease’s gene-expression “signature” and search for compounds that push gene activity in the opposite direction.

Two independent research groups did this and flagged GHK:

• Colorectal cancer. Researchers identified a 54-gene signature linked to metastasis in early-stage colorectal cancer. A Connectivity Map search predicted that GHK could reverse much of that signature [13]. This was a computational prediction, not a clinical test.
• Emphysema. Researchers found a gene-expression signature of lung tissue destruction in COPD and identified GHK as a compound predicted to reverse it. Follow-up lab experiments showed that GHK restored some tissue-remodeling functions in fibroblasts taken from COPD lungs [14].

Pickart’s reviews build on this work and state that GHK can alter the expression of at least 4,000 human genes [2, 5]. Phrases like “resets your DNA” usually trace back to this claim.

Here is the caution. Changing gene activity in cultured cells is not the same as improving health in a person. Connectivity Map results generate hypotheses. They tell scientists what might be worth testing, not what works. Many compounds change thousands of genes in cultured cells, and the direction of those changes doesn’t predict clinical benefit or safety. No human trial has shown that GHK-Cu treats cancer, COPD, cognitive decline, or any other disease.

How strong is the evidence?

Area	Main study types	Strength of evidence
Collagen / matrix biology	Cell culture, animal models	Moderate (preclinical only)
Skin aging (topical)	Small cosmetic studies, a few small RCTs	Low; mixed objective results
Wound healing	Animal studies; two older human RCTs	Low; one positive, one negative trial
Hair growth	Animal and lab studies, partly with a related peptide	Very low (no solid human trials)
Gene expression / disease reversal	Computational and cell studies	Hypothesis-generating only
Injectable use (any purpose)	No published controlled human trials found	Insufficient

Topical vs. injectable: an important distinction

When people talk about “GHK-Cu,” they may mean two very different things.

Topical cosmetic use means a cream or serum applied to the skin, usually at very low concentrations. The Cosmetic Ingredient Review Expert Panel assessed copper tripeptide-1 along with related peptides. It noted that typical use concentrations were under 10 parts per million and that safety testing was negative. The panel concluded that these ingredients are safe as used in cosmetics at current concentrations [3]. That conclusion covers safety, not effectiveness.

Injectable use is a different situation. It mostly happens in “anti-aging,” wellness, and biohacking settings. In reviewing GHK-Cu for injectable compounding, the FDA said compounded injectable GHK-Cu may carry a risk of immunogenicity (unwanted immune reactions) because of possible aggregation and peptide-related impurities. It also said there are limited human data to inform safety [15]. We found no published controlled human trials of injected GHK-Cu. A safety record for skin creams says nothing about putting the same molecule directly into the body.

Safety and unknowns

What is reasonably well supported:

• Topical products at cosmetic concentrations have been judged safe by the cosmetic industry’s independent expert panel [3]. As with any skincare ingredient, irritation or individual reactions are possible.
• Injectable products raise specific concerns about immune reactions and impurities, and there is little human data to judge them [15]. Products made outside regulated drug manufacturing offer no assurance of identity, purity, sterility, or dose.

What is uncertain:

• Long-term effects. No long-term human safety studies of GHK-Cu were found, especially for injectable or high-dose use.
• Growth signaling. The original 1973 paper reported growth stimulation in liver cancer tissue [1], while later computational work predicted anti-metastatic gene effects [13]. These findings don’t add up to a clear answer about cancer risk in either direction. That uncertainty is a reason for caution, not reassurance, especially for people with a history of cancer.
• Copper metabolism disorders. Wilson disease is an inherited condition in which the body can’t properly handle copper, so copper builds up in the liver and other organs [16]. We found no studies of GHK-Cu in people with Wilson disease. Cosmetic products contain very small amounts of copper. Still, anyone with Wilson disease or another copper-metabolism disorder should check with their specialist before using any copper-containing product, and especially before considering anything injected.
• Pregnancy, breastfeeding, and children. We found no safety data for these groups.

Regulatory status (as of November 2026)

As a cosmetic ingredient. In the U.S., cosmetic products and ingredients (other than color additives) do not need FDA approval before going on the market. A product’s legal status depends on its intended use. Claims that a product treats disease or changes the body’s structure or function, such as restoring hair growth, can make it a drug under the law [17]. That’s why cosmetic labels describe the “appearance” of wrinkles rather than promising to rebuild skin.

As a drug. GHK-Cu is not an FDA-approved drug for any condition.

Compounding. Pharmacies that compound medications from bulk ingredients not found in approved drugs work under an FDA interim policy. Under that policy, nominated substances are sorted into categories while FDA evaluates them. Category 1 means “under evaluation,” and Category 2 means the substance raises significant safety concerns. GHK-Cu’s status changed several times in 2026:

• According to FDA’s list updated May 14, 2026, GHK-Cu was removed from Category 1 on April 22, 2026, after its nominations were withdrawn. On May 5, 2026, one nominator clarified that it meant to withdraw only the injectable nomination. FDA then placed “GHK-Cu (except for injectable routes of administration)” back in Category 1 [18].
• Injectable GHK-Cu now appears on FDA’s safety-risk page among substances “nominated but withdrawn,” along with the immunogenicity and limited-human-data concerns described above [15]. It is not in Category 1.
• FDA has said it plans to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether GHK-Cu should be added to the official list of substances allowed for compounding [18].

Being in Category 1 is not FDA approval. It is not a finding that GHK-Cu is safe or effective. Regulatory policy in this area has been changing quickly, so check FDA’s current pages for updates.

Questions to ask your clinician

If you’re considering GHK-Cu, especially anything beyond an over-the-counter cosmetic, these questions can help:

1. What specific result am I hoping for, and is there human evidence for that use?
2. Are there treatments with stronger evidence for my concern, such as topical retinoids for photoaging or established treatments for hair loss or chronic wounds?
3. If this is an injectable product, what is its regulatory status, who made it, and what human safety data exist?
4. Do I have any condition, such as Wilson disease, liver disease, a history of cancer, or pregnancy, that changes the risk?
5. How will we judge whether it’s working, and when should I stop?

Bottom line

GHK-Cu is a real, naturally occurring peptide with an interesting and fairly consistent body of lab and animal research behind it. But human evidence is limited: a few small topical studies with mixed results, two older wound-healing trials pointing in opposite directions, and essentially no controlled human data for hair loss or for injectable use. The striking gene-expression findings generate hypotheses rather than prove anything. Much of the enthusiastic review literature comes from the discoverer’s own group.

Topical cosmetic products containing copper tripeptide-1 appear low-risk at typical concentrations, but their benefits are not well proven. Injectable GHK-Cu is a different matter: it is unapproved, it has raised specific safety concerns at FDA, and it lacks published human safety data.

This article is for educational purposes only and is not medical advice. Talk with a qualified healthcare professional before making decisions about any treatment.

References

1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-87. PubMed
2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PubMed
3. Johnson W, Bergfeld WF, Belsito DV, et al. Safety assessment of tripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 as used in cosmetics. Int J Toxicol. 2018;37(3 Suppl):90S-102S. DOI
4. Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. PubMed
5. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PubMed
6. Najafi N, Maatouk H, Vardanyan KG, et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu (glycyl-L-histidyl-L-lysine-copper complex) in topical microneedle delivery: a case for expanded clinical trials. Arch Intern Med Res. 2026;9(3):269-293. PubMed
7. Miller TR, Wagner JD, Baack BR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259. PubMed
8. Canapp SO Jr, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003;32(6):515-523. PubMed
9. Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-269. PubMed
10. Bishop JB, Phillips LG, Mustoe TA, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-257. PubMed
11. Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol. 1993;101(1 Suppl):143S-147S. PubMed
12. Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. PubMed
13. Hong Y, Downey T, Eu KW, et al. A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis. 2010;27(2):83-90. PubMed
14. Campbell JD, McDonough JE, Zeskind JE, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. PubMed
15. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of April 22, 2026. FDA
16. Alkhouri N, Gonzalez-Peralta RP, Medici V. Wilson disease: a summary of the updated AASLD Practice Guidance. Hepatol Commun. 2023;7(6):e0150. PubMed
17. U.S. Food and Drug Administration. Is it a cosmetic, a drug, or both? (Or is it soap?). Content current as of September 11, 2024. FDA
18. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026. FDA (PDF)